QUEBEC, Dec. 6 /CNW Telbec/ - The Association québécoise de la
dégénérescence maculaire (AQDM) commends the Government of Quebec for listing
Lucentis under the provincial drug benefit plan as a treatment for wet
age-related macular degeneration (AMD).
Quebec is demonstrating leadership in this area, as it is the first
province in Canada to cover this innovative drug.
The decision to add Lucentis to the list of covered medications means
that the majority of those suffering from wet AMD can now hope to combat the
potentially devastating effects of the illness.
AMD is a degenerative disease of the retina that affects central vision.
The disease can often lead to a loss of vision in just a few months. More than
290,000 people in Canada are affected by wet AMD and this number will likely
increase significantly in the coming years due to the aging of the population.
Lucentis is the first treatment for wet AMD that has been demonstrated
not only to slow the advancement of the disease but also to potentially
improve vision in many patients.
"We can now access a treatment that will give people hope of changing the
outcome of their disease," explains Gérard St-Denis, President of the AQDM.
"We hope that all Quebec patients suffering from wet AMD will benefit from
Lucentis as soon as possible before the disease has progressed and has a major
impact on their vision."
Mr. St-Denis adds that Quebecers with wet AMD should consult their
doctors right away to find out if this new treatment is suitable in their
The Association québécoise de la dégénérescence maculaire is a non-profit
organization whose mission is to foster the autonomy and facilitate the mutual
support of those with macular degeneration. The Association refers these
individuals to existing medical, technological and social resources. It also
informs patients about prevention methods and treatment as well as research
carried out around the world. The AQDM's goal is to educate health care
practitioners and the general public about the challenges of this largely
For further information:
For further information: Marie-Sophie Villeneuve, (514) 895-1040,
email@example.com; If you suffer from AMD and would like more
information, call 1 866-867-9389 or visit www.aqdm.org